Reveals tumor cell responses to PARP inhibitors in advanced prostate cancer, suggesting new treatment strategies.
Background/Objectives: Though PARP inhibition has improved the management of advanced prostate cancer, patient outcomes may be modest and disease progression on treatment is common. We sought to improve understanding of tumor cell response to PARP inhibition to support development of novel strategies to enhance and/or prolong PARP inhibitor (PARPi) efficacy. Methods: Cell viability assays and microscopy were used for initial characterization of PARPi response in models of advanced prostate cancer. RNA sequencing was performed to investigate time-dependent transcriptomic changes induced by PARP inhibition. Western blots, flow cytometry, and both additional viability assays and microscopy were used to validate RNA sequencing results and test potential
No takes yet. Share an insight, caveat, or question.
Gonzalez et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: